GlaxoSmithKline honors cancer research pioneer Gianni Bonadonna with new ASCO Award and Fellowship

June 01, 2007

CHICAGO - June 1, 2007 - GlaxoSmithKline Oncology (GSK), in support of The American Society of Clinical Oncology (ASCO) and The ASCO Foundation, proudly announce today the creation of the Gianni Bonadonna Breast Cancer Award and Fellowship as a tribute to Dr. Bonadonna's outstanding contributions in the field of cancer research. The annual Award and Fellowship will acknowledge clinical or translational researchers of merit in the field of breast cancer and enable emerging investigators to undertake new patient-oriented research under the mentorship of the awardees. The new Award, which is supported by a multi-year grant in excess of one million dollars from GSK, will be unveiled at the ASCO Annual Meeting in Chicago and the first awardee will be announced at the 2007 ASCO Breast Cancer Symposium in September.

Dr. Gianni Bonadonna, Chair for the Committee on Prospective Clinical Trials at the Istituto Nazionale Tumori in Milan, Italy, is one of the most important figures in modern-day medical oncology. His significant achievements during a long esteemed career include his ground-breaking research in adjuvant treatment of breast cancer and the development of the combination chemotherapy regimen that remains the gold-standard treatment for Hodgkin's disease today.

"GSK is delighted and privileged to support ASCO and The ASCO Foundation on this new award that honors the legacy of one of the giants of medical oncology," said Paolo Paoletti, MD, Senior Vice President of the Oncology Medicine Development Center at GlaxoSmithKline. "Dr. Bonadonna is an exceptional scientist, clinician and humanitarian. His revolutionary and courageous approaches to early stage cancer research opened up new avenues for the treatment of breast cancer, resulting in improved standards of care and longer lives for thousands of patients. His tangible impact on the progress we have made in cancer research continues to be felt today."

About the Gianni Bonadonna Breast Cancer Award and Fellowship 'The Gianni Bonadonna Breast Cancer Award and Lecture', a $10,000 award, will be presented annually to a researcher of merit in the field of breast cancer. The award will be accompanied by a Fellowship grant, presented to an early-career breast cancer researcher at the institution with which the awardee is affiliated. 'The Gianni Bonadonna Breast Cancer Research Fellowship' will consist of a one-year grant of at least $50,000 in support of the fellow's research.

In 1972 Bonadonna designed a new combination chemotherapy regimen for Hodgkin's disease known as ABVD (adriamycin, bleomycin, vinblastine and dacarbazine) that proved to be superior to the existing standard of care at the time (the MOPP regimen). In 1973 he designed and conducted the first randomized study to test the activity of the CMF (cyclophosphamide, methotrexate and fluorouracil) combination chemotherapy as an adjuvant treatment in node-positive operable breast cancer. Adjuvant CMF proved to be effective in significantly reducing the risk of disease recurrence and death over a prolonged period of time (30 years).

"Without Gianni Bonadonna's initial work in demonstrating the activity of chemotherapy, we would not be where we are today in terms of the management and the cure of breast cancer," said Gabriel Hortobagyi, president of ASCO. "Bonadonna's legacy is one of focus, persistence, passion, innovation and creativity. That's a tall order for most new members of our profession but clearly is a combination of attributes that make Dr. Gianni Bonadonna a role model for oncology professionals of the future."

"I have always tried to instil in my colleagues and students that it is most important to treat the human being and not just the disease. I am grateful to ASCO and GSK for this honor and I hope this Award symbolizes and sends that message to oncology professionals of today and the future," said Dr. Bonadonna.
-end-
About GlaxoSmithKline: GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better, and live longer.

For company information: visit GlaxoSmithKline at http://www.gsk.com

GSK in Oncology GSK Oncology is dedicated to producing innovations in cancer that will make profound differences in the lives of patients. Through GSK's "bench to bedside" approach, we are transforming the way treatments are discovered and developed, resulting in one of the most robust pipelines in the oncology sector. Our worldwide research in oncology includes partnerships with more than 160 cancer centers. GSK is developing a new generation of patient focused cancer treatments in prevention, supportive care, chemotherapy and targeted therapies.

Media contact:robin.e.fastenau@gsk.com

GAEA Initiative

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.